Maxim Group Initiates Coverage on Scienture (NASDAQ:SCNX)

Stock analysts set a 'buy' rating and $1.50 price target on the healthcare company's shares.

Published on Feb. 24, 2026

Got story updates? Submit your updates here. ›

Stock analysts at Maxim Group have initiated coverage on shares of Scienture (NASDAQ:SCNX), a healthcare company focused on addressing underserved patients and indications through novel product concepts and innovation. The brokerage set a 'buy' rating and a $1.50 price target on the stock, suggesting a potential upside of nearly 300% from the previous close.

Why it matters

This analyst coverage and positive rating could generate increased investor interest and trading volume in Scienture's stock, potentially boosting the company's visibility and access to capital as it continues to develop its healthcare products and services.

The details

Maxim Group's price target of $1.50 per share for Scienture represents a significant premium over the stock's previous closing price. The analysts' 'buy' rating comes despite a 'sell (e+)' rating from Weiss Ratings and a downgrade to 'sell' from Wall Street Zen. Overall, the analyst community is currently split on Scienture, with one 'buy' and one 'sell' rating.

  • Maxim Group initiated coverage on Scienture on Tuesday, February 24, 2026.
  • Weiss Ratings issued a 'sell (e+)' rating on Scienture on Monday, December 29, 2025.
  • Wall Street Zen lowered its rating on Scienture to 'sell' on Sunday, January 25, 2026.

The players

Maxim Group

A brokerage firm that has initiated coverage on Scienture with a 'buy' rating and $1.50 price target.

Scienture Holdings, Inc.

A healthcare company focused on addressing underserved patients and indications through novel product concepts and innovation. The company was founded in 2005 and is headquartered in Lutz, Florida.

Weiss Ratings

A research firm that has issued a 'sell (e+)' rating on Scienture's stock.

Wall Street Zen

A research firm that has downgraded Scienture's stock to a 'sell' rating.

Geode Capital Management LLC

A hedge fund that recently increased its stake in Scienture by 264.3%, now owning approximately 0.78% of the company's stock.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

This analyst coverage and rating on Scienture's stock highlights the potential upside that investors see in the company's healthcare products and services, even as the overall analyst community remains divided on the stock's prospects. The increased institutional investment from Geode Capital Management also suggests growing interest in Scienture among larger investors.